Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Rheumatology
Volume 2017, Article ID 5386797, 6 pages
https://doi.org/10.1155/2017/5386797
Case Report

Effective Administration of Rituximab in Anti-MDA5 Antibody–Positive Dermatomyositis with Rapidly Progressive Interstitial Lung Disease and Refractory Cutaneous Involvement: A Case Report and Literature Review

1Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto 390-8621, Japan
2Department of Dermatology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto 390-8621, Japan

Correspondence should be addressed to Yasuhiro Shimojima; pj.ca.u-uhsnihs@ijomihsy

Received 31 July 2017; Accepted 24 September 2017; Published 31 October 2017

Academic Editor: Gregory J. Tsay

Copyright © 2017 Yuka Ogawa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. C. Dalakas and R. Hohlfeld, “Polymyositis and dermatomyositis,” Lancet, vol. 362, no. 9388, pp. 971–982, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. P. Gerami, J. M. Schope, L. McDonald, H. W. Walling, and R. D. Sontheimer, “A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sine myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies,” Journal of the American Academy of Dermatology, vol. 54, no. 4, pp. 597–613, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Sato, M. Hirakata, M. Kuwana et al., “Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis,” Arthritis and Rheumatism, vol. 52, no. 5, pp. 1571–1576, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. T. Gono, Y. Kawaguchi, T. Satoh et al., “Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis,” Rheumatology, vol. 49, no. 9, pp. 1713–1719, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. Y. Muro, K. Sugiura, K. Hoshino, and M. Akiyama, “Disappearance of anti-MDA-5 autoantibodies in clinically amyopathic DM/interstitial lung disease during disease remission,” Rheumatology, vol. 51, no. 5, pp. 800–804, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. H. Cao, M. Pan, Y. Kang et al., “Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-melanoma differentiation-associated gene 5 antibody,” Arthritis Care & Research, vol. 64, no. 10, pp. 1602–1610, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. H. Kameda, H. Nagasawa, H. Ogawa et al., “Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis,” Journal of Rheumatology, vol. 32, no. 9, pp. 1719–1726, 2005. View at Google Scholar
  8. Y. Matsuki, H. Yamashita, Y. Takahashi et al., “Diffuse alveolar damage in patients with dermatomyositis: a six-case series,” Modern Rheumatology, vol. 22, no. 2, pp. 243–248, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. Y. Shimojima, W. Ishii, M. Matsuda, D. Kishida, and S. I. Ikeda, “Effective use of calcineurin inhibitor in combination therapy for interstitial lung disease in patients with dermatomyositis and polymyositis,” Journal of Clinical Rheumatology, vol. 23, no. 2, pp. 87–93, 2017. View at Publisher · View at Google Scholar
  10. C. V. Oddis, A. M. Reed, R. Aggarwal et al., “Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial,” Arthritis and Rheumatism, vol. 65, no. 2, pp. 314–324, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. R. Aggarwal, P. Loganathan, D. Koontz, Z. Qi, A. M. Reed, and C. V. Oddis, “Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab,” Rheumatology, vol. 56, no. 2, pp. 247–254, 2017. View at Publisher · View at Google Scholar
  12. H. Andersson, M. Sem, M. B. Lund et al., “Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease,” Rheumatology, vol. 54, no. 8, pp. 1420–1428, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. I. Marie, S. Dominique, A. Janvresse, H. Levesque, and J. F. Menard, “Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome,” Respiratory Medicine, vol. 106, no. 4, pp. 581–587, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Clottu, E. Laffitte, C. Prins, and C. Chizzolini, “Response of mucocutaneous lesions to rituximab in a case of melanoma differentiation antigen 5-related dermatomyositis,” Dermatology, vol. 225, no. 4, pp. 376–380, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. R. Watanabe, T. Ishii, K. Araki et al., “Successful multi-target therapy using corticosteroid, tacrolimus, cyclophosphamide, and rituximab for rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis,” Modern Rheumatology, vol. 26, no. 3, pp. 465-466, 2016. View at Publisher · View at Google Scholar · View at Scopus
  16. B. Gil, L. Merav, L. Pnina, and G. Chagai, “Diagnosis and treatment of clinically amyopathic dermatomyositis (CADM): a case series and literature review,” Clinical Rheumatology, vol. 35, no. 8, pp. 2125–2130, 2016. View at Publisher · View at Google Scholar · View at Scopus
  17. Y. Koichi, Y. Aya, U. Megumi et al., “A case of anti-MDA5-positive rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis ameliorated by rituximab, in addition to standard immunosuppressive treatment,” Modern Rheumatology, vol. 27, no. 3, pp. 536–540, 2017. View at Publisher · View at Google Scholar
  18. K. Tokunaga and N. Hagino, “Dermatomyositis with rapidly progressive interstitial lung disease treated with rituximab: a report of 3 cases in Japan,” Internal Medicine, vol. 56, no. 11, pp. 1399–1403, 2017. View at Publisher · View at Google Scholar
  19. D. Fiorentino, L. Chung, J. Zwerner, A. Rosen, and L. Casciola-Rosen, “The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study,” Journal of the American Academy of Dermatology, vol. 65, no. 1, pp. 25–34, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Sato, A. Murakami, A. Kuwajima et al., “Clinical utility of an enzyme-linked immunosorbent assay for detecting anti-melanoma differentiation-associated gene 5 autoantibodies,” PLoS One, vol. 11, no. 4, p. e0154285, 2016. View at Publisher · View at Google Scholar · View at Scopus
  21. T. Kotani, S. Makino, T. Takeuchi et al., “Early intervention with corticosteroids and cyclosporin A and 2-hour postdose blood concentration monitoring improves the prognosis of acute/subacute interstitial pneumonia in dermatomyositis,” Journal of Rheumatology, vol. 35, no. 2, pp. 254–259, 2008. View at Google Scholar
  22. T. Kurita, S. Yasuda, K. Oba et al., “The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis,” Rheumatology, vol. 54, no. 1, pp. 39–44, 2015. View at Publisher · View at Google Scholar · View at Scopus
  23. T. Kurita, S. Yasuda, O. Amengual, and T. Atsumi, “The efficacy of calcineurin inhibitors for the treatment of interstitial lung disease associated with polymyositis/dermatomyositis,” Lupus, vol. 24, no. 1, pp. 3–9, 2015. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Sato, K. Hoshino, T. Satoh et al., “RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease,” Arthritis and Rheumatism, vol. 60, no. 7, pp. 2193–2200, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. P. Engel, J. A. Gomez-Puerta, M. Ramos-Casals, F. Lozano, and X. Bosch, “Therapeutic targeting of B cells for rheumatic autoimmune diseases,” Pharmacological Reviews, vol. 63, no. 1, pp. 127–156, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. R. Stasi, G. Del Poeta, E. Stipa et al., “Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura,” Blood, vol. 110, no. 8, pp. 2924–2930, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. N. Jacob and W. Stohl, “Autoantibody-dependent and autoantibody-independent roles for B cells in systemic lupus erythematosus: past, present, and future,” Autoimmunity, vol. 43, no. 1, pp. 84–97, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Fasano, P. Gordon, R. Hajji, E. Loyo, and D. A. Isenberg, “Rituximab in the treatment of inflammatory myopathies: a review,” Rheumatology, vol. 56, no. 1, pp. 26–36, 2017. View at Publisher · View at Google Scholar
  29. T. Takada, A. Aoki, K. Asakawa et al., “Serum cytokine profiles of patients with interstitial lung disease associated with anti-CADM-140/MDA5 antibody positive amyopathic dermatomyositis,” Respiratory Medicine, vol. 109, no. 9, pp. 1174–1180, 2015. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Sato, M. Kuwana, T. Fujita, and Y. Suzuki, “Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease,” Modern Rheumatology, vol. 23, no. 3, pp. 496–502, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. T. Gono, Y. Kawaguchi, M. Hara et al., “Increased ferritin predicts development and severity of acute interstitial lung disease as a complication of dermatomyositis,” Rheumatology, vol. 49, no. 7, pp. 1354–1360, 2010. View at Publisher · View at Google Scholar · View at Scopus